News

Public · Published

Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories

Calidi Biotherapeutics presented new CLD-401 data at the ESMO Congress 2026 in Madrid, showing a single dose caused tumor regression and complete response in 80% of mice in an EMT6 breast tumor model, with about 10 ng/mL of EpCAM-targeted TCE made inside tumors after IV delivery.

Published:

Updated:

What happened

Calidi Biotherapeutics presented new CLD-401 data at the ESMO Congress 2026 in Madrid, showing a single dose caused tumor regression and complete response in 80% of mice in an EMT6 breast tumor model, with about 10 ng/mL of EpCAM-targeted TCE made inside tumors after IV delivery.

Confirmed

Global impact / market context

If this early mouse result holds in people, Calidi could offer a way to make powerful immune-activating proteins inside tumors instead of giving them systemically, which means it may reach more solid tumors while avoiding whole-body side effects and lowering treatment costs.

Analyst inference

The data support the growing interest in T-cell engagers, which are drugs that help immune cells attack tumors, but they remain preclinical mouse results. Investors will likely weigh them against Calidi's need for partnerships and cash to fund the costly human trials required before any approval.

Analyst inference

What to watch

  1. Calidi said it is pursuing strategic partnerships to speed clinical development and broaden its RedTail platform, so news of a signed partner or funding deal would be a concrete signal the program can advance beyond preclinical mouse studies. Confirmed
  2. Watch whether Calidi announces plans for human trials of CLD-401, including timelines and the cancers targeted, because a clear clinical path would show whether the 80% mouse response can be tested in patients. Proposed
  3. Track Calidi's cash position and spending in future updates, since human trials are expensive; limited cash available, meaning the money on hand to pay bills, could force delays, dilution for shareholders, or a partnership on less favorable terms. Analyst inference

Evidence